Application of an intermediate concentration of cyclophosphamide does not specifically deplete regulatory T cells in a mouse experimental model
2023
Тип документа:
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт:
Cyclophosphamide (CP) is a cytostatic, widely used to treat different carcinomas and autoimmune diseases. It is
commonly used in experimental designs modeling immunosuppression in laboratory animals, with different approaches for
CP treatment but without a consensus on the dose, timing, and route of administration. We aimed to establish if treatment
with CP in C57BL/6 mice depletes regulatory T cells (Tregs). Tregs are a crucial component of the immune system that
helps maintain immune tolerance and prevent excessive immune reactions. They are significant in autoimmune diseases,
allergies, and immune-related therapies. CP was applied intraperitoneally (i.p.) twice in a 5-day interval in doses of 100 mg/
kg. Monitoring of Treg prevalence in peripheral blood after each treatment and in the spleen after the second treatment with
CP revealed a drop in the number of Tregs after two doses of CP because of the decreased number of total lymphocytes but
not as a specific response of the Tregs. The prevalence of Tregs in peripheral blood after CP treatment mirrored the change
in Treg number in the spleen. CP treatment induced a decrease in the number of CD3+ cells in the spleen while increasing
their proportion, indicating that CP affected the B lymphocyte population rather than T cells. Our results suggest that CP
treatment cannot be used as a specific Treg-depleting agent in the C57BL/6 animal model.
Кључне речи:
cyclophosphamide; immunosuppression; regulatory T cells; lymphocytes; mouse experimental modelИзвор:
Archive of Biological Sciences, 2023, 75, 4, 397-406Финансирање / пројекти:
- Министарство науке, технолошког развоја и иновација Републике Србије, институционално финансирање - 200007 (Универзитет у Београду, Институт за биолошка истраживања 'Синиша Станковић') (RS-MESTD-inst-2020-200007)